Feinstein Institute for Medical Research

No. 358: Softheon speeding, Central Islip redeveloping and Vision Long Island seeing things a little differently

  Done deal: You’ve made it, dear reader – it’s Friday, Nov. 16, another week of socioeconomic progress is in the books and another weekend (followed by a blessedly short holiday week) lies ahead. Make a day of it: To our Icelandic readers, happy Dagur íslenskrar tungu. To all members of the United Nations, remember to observe the International Day for Tolerance. It’s also National Fast Food Day. Only in America. Live at five: Now…


NIH to Feinstein: Stick out that chest (bioelectrically)

By GREGORY ZELLER // With new treatments for obesity, heart failure and a host of other conditions in sight, a Feinstein Institute researcher will zero in on specific abdominal targets in a new “precision bioelectronic medicine” study. North Shore University Hospital and Long Island Jewish Medical Center Chief of Gastroenterology Larry Miller, who also directs the Gastroenterology Laboratory at the Feinstein Institute for Medical Research, has received a $1.4 million National Institutes of Health grant…


Feinstein researchers eye chronic post-storm despair

By GREGORY ZELLER // A team of Feinstein Institute for Medical Research investigators is digging deep into the mental toll natural disasters take on survivors. The team – led by Rebecca Schwartz, an associate investigator at the Manhasset-based Feinstein Institute, R&D division of the Northwell Health system – presented its findings during a roundtable discussion at the American Public Health Association’s annual meeting, held this week in California. According to the research, exposure to natural…


Researchers eye genetic factors in schizophrenia drugs

By GREGORY ZELLER // A new study by Feinstein Institute for Medical Research scientists suggests that a patient’s response to antipsychotic pharmaceuticals can be predicted by genetic predispositions. Schizophrenia – characterized by delusions, hallucinations and disorganized thoughts – is one of the leading causes of disability in the United States. Antipsychotic pharmaceuticals are a common treatment option, but such therapies are often “given without guidance from lab tests to show effectiveness, as is common in…


No. 349: Canada’s new high, Sikes’ new heights and LineaRX’s highest hopes (plus, repainting President Trump)

  Middle ground: Welcome to Wednesday, dear readers, and the halfway point of another exciting week of socioeconomic innovation. October 17 is in full swing, marking the 25th anniversary of the International Day for the Eradication of Poverty, a U.N. General Assembly effort to address shortages of basic necessities (i.e.: food, clothing, shelter) around the globe and reinforce the notion that poverty and human-rights abuses routinely coexist. Learn more here. Eye of the beholder: On…


At Northwell, redefining the shape of things to come

By GREGORY ZELLER // A powerful new 3D printing system is providing Northwell Health doctors hyper-realistic surgical models, easing patients’ minds and saving millions of dollars in lost operating-room time. That’s the assessment from the New Hyde Park-based health system, which this week noted it has “doubled down” on 3D printing technologies provided by Massachusetts-based developer and manufacturer Formlabs. Specifically, Northwell Health – already a Formlabs customer – has incorporated the tech firm’s powerful Form…


No. 339: Innovation (and procreation) in Russia, the ‘Best Colleges’ on Long Island and strange things on Cynthia Nixon’s bagel

Fair-to-middling: Welcome to Wednesday, dear readers, and the midpoint of another exciting workweek. We trust yours is, at least, slightly above average. It’s Sept. 12 out there, marking the international observance of Mindfulness Day, which promotes the notion of careful consideration. Why don’t you just think about that for a bit. Putin the “Mother” in “Mother Russia”: It’s also the Day of Procreation in Russia, which stems from a 2006 speech in which Vlad the…


For lupus patients, a possible ACE in the hole

By GREGORY ZELLER // A common pharmaceutical treatment for hypertension could be the key to preserving brain function in lupus patients. So says data published this month in the Journal of Experimental Medicine by an international team of scientists led by the redoubtable Betty Diamond, head of the Feinstein Institute for Medical Research’s Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases and a professor of molecular medicine at the Donald and Barbara Zucker School of Medicine…


No. 335: Phooey chop, King of Pop and a phone flop – and why is Hank Foley so big on blockchain, anyway?

Middle of the road: Welcome to the midpoint of another sweltering summer workweek, dear reader. Your three-day holiday weekend is now clearly in sight. It’s already Aug. 29 out there, and not only is this week half over, but at midnight tomorrow night, 2018 will be two-thirds kaput. That’s fairly amazing. Best of luck: For those keeping score, Wednesday is the best day of the week for airplane travel, grocery shopping, weighing yourself, getting married…


Feinstein doc eyes telehealth for Hispanic diabetes

By GREGORY ZELLER // It’s not precisely the Telemundo of telemedicine, but a Long Island scientist will spend some $3 million of the Patient-Centered Outcomes Research Institute’s money exploring telehealth protocols for Hispanic diabetes patients. The PCORI, a government-funded (but non-government) Washington-based organization that supports and investigates various medical treatments, is backing Feinstein Institute for Medical Research professor Renee Pekmezaris’ study of home telemonitoring for Hispanic-community patients living with type 2 diabetes, the most common…


No. 332: Hitting it big in vagus, hitting it bigger at SBU, commercial support for the disabled and eternal respect for Aretha

Well done: It’s Friday, dear readers, and once again, you’ve conquered the five-day minefield that is the American workweek. To mark your achievement and put you in a proper Friday mood, ladies and gentlemen … The Cure! Continental breakfast: We’re sending a special hello this Aug. 17 to all of our South American readers – whether you’re celebrating Engineer’s Day in Colombia or Flag Day in Bolivia, please celebrate responsibly. Here in the States, it’s…


No. 331: A retail first at Roosevelt Field, phone calls from outer space and why dumping debris in LI waters is good (sometimes)

Hump-hopping: Welcome to Wednesday, dear readers, as we speed through another exciting (and mercilessly damp) week of socioeconomic innovation. It’s Aug. 15 out there, and today we observe the 73rd anniversary of Victory Over Japan Day. Sorta. (It could be Aug. 15, the date Japan officially announced its surrender, but it could also be Aug. 14 – the surrender date in the States, because of time zones – or possibly Sept. 2, the date Japan…


No. 324: Vikings on Mars, FSC on the job, Sanguistat on the move, and why Freeport is happy to be on the outs

Well done: Very impressive, intrepid reader – you’ve made it to the end of another productive workweek, and earned yourself another glorious weekend. It’s July 20 out there, and if you said “knight to king 4,” good move, since today is of course International Chess Day, commemorating the launch of the World Chess Federation on this date in 1924. The Eagle has landed: Today also marks the 49th anniversary of one of mankind’s greatest scientific…


Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…


Feinstein prof snags $3.5M for bladder-cancer effort

By GREGORY ZELLER // The National Institutes of Health is backing a Long Island-based researcher’s efforts to develop a first-of-its-kind care program for post-surgical bladder cancer patients. Michael Diefenbach, a fellow of both the Society of Behavioral Medicine and the Academy of Behavioral Medicine Research and a professor at Northwell Health’s Manhasset-based Feinstein Institute for Medical Research, has earned a five-year, $3.5 million grant from the NIH’s National Cancer Institute. The funds will be used…